2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

2:30PM-4:00PM: Abstract Number: 3142

Tocilizumab Enhances Regulatory T-Cell Activation and Proliferation in Giant Cell Arteritis

Vasculitis III

2:30PM-4:00PM: Abstract Number: 3117

Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis - CoMorbidities

2:30PM-4:00PM: Abstract Number: 3151

Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) Modules for Use in Childhood-Onset Lupus

ACR/ARHP Combined Abstract Session: Pediatric Rheumatology

2:30PM-4:00PM: Abstract Number: 3150

Virtual Peer-to-Peer Mentoring Support for Adolescents with Juvenile Idiopathic Arthritis: The Virtual Peer-to-Peer Program

ACR/ARHP Combined Abstract Session: Pediatric Rheumatology

2:30PM-4:00PM: Abstract Number: 3125

White Matter Magnetization Transfer Ratio Histogram Peak Height Helps Identifying Inflammatory Neuropsychiatric Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Neuropsychiatric Lupus

4:30PM-6:00PM: Abstract Number: 3185

A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients in the United States

Rheumatoid Arthritis - Clinical Aspects V: Goal = Remission

4:30PM-6:00PM: Abstract Number: 3233

A Comparison of Interobserver Agreement Between Advanced Practice Physiotherapists and Rheumatologists in the Detection of Axial Spondyloarthritis

ARHP IV: Clinical Practice and Patient Care

4:30PM-6:00PM: Abstract Number: 3L

A Randomised Controlled Trial of the Clinical Effectiveness, Safety and Cost-Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis

ACR Late-breaking Abstract Session

4:30PM-6:00PM: Abstract Number: 3218

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus - Clinical Aspects and Treatment VI: Novel Therapies

4:30PM-6:00PM: Abstract Number: 3231

A Systematic Review of the Persuasive Design Principles Used in Health Apps for Arthritis

ARHP IV: Clinical Practice and Patient Care

4:30PM-6:00PM: Abstract Number: 3220

Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial

Systemic Lupus Erythematosus - Clinical Aspects and Treatment VI: Novel Therapies

4:30PM-6:00PM: Abstract Number: 3223

Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus - Clinical Aspects and Treatment VI: Novel Therapies

4:30PM-6:00PM: Abstract Number: 3167

Association of the Apolipoprotein A1-C3-A4 Gene Cluster with the Risk of Gout: Evidence for a Causal Role in Gout

Metabolic and Crystal Arthropathies II: Mechanisms and Associations

4:30PM-6:00PM: Abstract Number: 3207

Axial Disease in Psoriatic Arthritis: A Clinical and Radiographic Comparison with Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects, Imaging and Biomarkers

4:30PM-6:00PM: Abstract Number: 3157

B Cell Profile As a Biomarker of Disease Segmentation and Flare Prognosis in SLE

B cell Biology and Targets in Autoimmune Disease: Novel B cell roles in RA and SLE

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].